Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial

INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP

Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101

TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights

Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme

Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial

Novocure and Verastem to evaluate combination therapy for pancreatic cancer

US WorldMeds acquires Orbus Therapeutics

Astellas and Audax Biosciences sign exclusive option and licence agreement for DAX-044

Thor Medical signs three-year isotope supply agreement with Medicines Discovery Catapult

Enhertu wins EU approval for HER2-positive early breast cancer treatment

Riboscience reports Phase 1a/b overall survival data for ENPP1 inhibitor RBS2418

Citius Oncology reports growth in LYMPHIR unit shipments to US wholesalers

Genmab reports 28.2-month median overall survival with petosemtamab combination in Phase 2 trial

Akeso presents Phase III HARMONi-GI1 trial results in biliary tract cancer at ESMO 2026